LOX-1 Regulation of H-type Vascular Endothelial Cell Regeneration in Hyperglycemia

Overview

Journal Acta Diabetol

Specialty Endocrinology

Date 2024 Jan 20

PMID 38244081

Authors

Haoyue Lei

Wenhui Guo

Youzhuo Pan

Xun Lu

Qi Zhang

Affiliations

Soon will be listed here.

Abstract

Aims: Diabetic osteoporosis (DOP) is the most common secondary form of osteoporosis. Diabetes mellitus affects bone metabolism; however, the underlying pathophysiological mechanisms remain unclear. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) expression is upregulated in conditions characterized by vascular injury, such as atherosclerosis, hypertension, and diabetes. Additionally, Notch, HIF-1α, and VEGF are involved in angiogenesis and bone formation. Therefore, we aimed to investigate the expression of Notch, HIF-1α, and VEGF in the LOX-1 silencing state.

Methods: Rat bone H-type vascular endothelial cells (THVECs) were isolated and cultured in vitro. Cell identification was performed using immunofluorescent co-expression of CD31 and Emcn. Lentiviral silencing vector (LV-LOX-1) targeting LOX-1 was constructed using genetic recombination technology and transfected into the cells. The experimental groups included the following: NC group, HG group, LV-LOX-1 group, LV-CON group, HG + LV-LOX-1 group, HG + LV-CON group, HG + LV-LOX-1 + FLI-06 group, HG + LV-CON + FLI-06 group, HG + LV-LOX-1 + LW6 group, and HG + LV-CON + LW6 group. The levels of LOX-1, Notch, Hif-1α, and VEGF were detected using PCR and WB techniques to investigate whether the expression of LOX-1 under high glucose conditions has a regulatory effect on downstream molecules at the gene and protein levels, as well as the specific molecular mechanisms involved.

Results: High glucose (HG) conditions led to a significant increase in LOX-1 expression, leading to inhibition of angiogenesis, whereas silencing LOX-1 can reverse this phenomenon. Further analysis reveals that changes in LOX-1 will promote changes in Notch/HIF-1α and VEGF. Moreover, Notch mediates the activation of HIF-1α and VEGF.

Conclusions: The activation of LOX-1 and the inhibition of Notch/HIF-1α/VEGF in THVECs are the main causes of DOP. These findings contribute to our understanding of the pathogenesis of DOP and offer a novel approach for preventing and treating osteoporosis.

References

Zimmet P, Alberti K, Magliano D, Bennett P . Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol. 2016; 12(10):616-22. DOI: 10.1038/nrendo.2016.105. View

Parizad N, Baghi V, Baghban Karimi E, Gheshlagh R . The prevalence of osteoporosis among Iranian postmenopausal women with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab Syndr. 2019; 13(4):2607-2612. DOI: 10.1016/j.dsx.2019.07.036. View

Fajardo R . Is Diabetic Skeletal Fragility Associated with Microvascular Complications in Bone?. Curr Osteoporos Rep. 2017; 15(1):1-8. DOI: 10.1007/s11914-017-0341-8. View

Pagnotti G, Styner M, Uzer G, Patel V, Wright L, Ness K . Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity. Nat Rev Endocrinol. 2019; 15(6):339-355. PMC: 6520125. DOI: 10.1038/s41574-019-0170-1. View

Zheng Z, Chen Y, Wu D, Wang J, Lv M, Wang X . Development of an Accurate and Proactive Immunomodulatory Strategy to Improve Bone Substitute Material-Mediated Osteogenesis and Angiogenesis. Theranostics. 2018; 8(19):5482-5500. PMC: 6276091. DOI: 10.7150/thno.28315. View

Kusumbe A, Ramasamy S, Adams R . Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature. 2014; 507(7492):323-328. PMC: 4943525. DOI: 10.1038/nature13145. View

Peng Y, Wu S, Li Y, Crane J . Type H blood vessels in bone modeling and remodeling. Theranostics. 2020; 10(1):426-436. PMC: 6929606. DOI: 10.7150/thno.34126. View

Maes C . Role and regulation of vascularization processes in endochondral bones. Calcif Tissue Int. 2013; 92(4):307-23. DOI: 10.1007/s00223-012-9689-z. View

Grosso A, Burger M, Lunger A, Schaefer D, Banfi A, Di Maggio N . It Takes Two to Tango: Coupling of Angiogenesis and Osteogenesis for Bone Regeneration. Front Bioeng Biotechnol. 2017; 5:68. PMC: 5675838. DOI: 10.3389/fbioe.2017.00068. View

10.

Jin P, Cong S . LOX-1 and atherosclerotic-related diseases. Clin Chim Acta. 2019; 491:24-29. DOI: 10.1016/j.cca.2019.01.006. View

11.

Xu S, Ogura S, Chen J, Little P, Moss J, Liu P . LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci. 2012; 70(16):2859-72. PMC: 4142049. DOI: 10.1007/s00018-012-1194-z. View

12.

Mehta J, Chen J, Hermonat P, Romeo F, Novelli G . Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res. 2005; 69(1):36-45. DOI: 10.1016/j.cardiores.2005.09.006. View

13.

Pugh C, Ratcliffe P . New horizons in hypoxia signaling pathways. Exp Cell Res. 2017; 356(2):116-121. PMC: 5653532. DOI: 10.1016/j.yexcr.2017.03.008. View

14.

Ramasamy S, Kusumbe A, Wang L, Adams R . Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature. 2014; 507(7492):376-380. PMC: 4943529. DOI: 10.1038/nature13146. View

15.

Gao F, Mao T, Zhang Q, Han J, Sun W, Li Z . H subtype vascular endothelial cells in human femoral head: an experimental verification. Ann Palliat Med. 2020; 9(4):1497-1505. DOI: 10.21037/apm-20-121. View

16.

Feng W, Liu S, Zhang C, Xia Q, Yu T, Zhu D . Comparison of cerebral and cutaneous microvascular dysfunction with the development of type 1 diabetes. Theranostics. 2019; 9(20):5854-5868. PMC: 6735377. DOI: 10.7150/thno.33738. View

17.

Tousoulis D, Papageorgiou N, Androulakis E, Siasos G, Latsios G, Tentolouris K . Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol. 2013; 62(8):667-76. DOI: 10.1016/j.jacc.2013.03.089. View

18.

Shanbhogue V, Hansen S, Frost M, Brixen K, Hermann A . Bone disease in diabetes: another manifestation of microvascular disease?. Lancet Diabetes Endocrinol. 2017; 5(10):827-838. DOI: 10.1016/S2213-8587(17)30134-1. View

19.

Shanbhogue V, Hansen S, Frost M, Jorgensen N, Hermann A, Henriksen J . Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. Eur J Endocrinol. 2015; 174(2):115-24. DOI: 10.1530/EJE-15-0860. View

20.

Zhang J, Pan J, Jing W . Motivating role of type H vessels in bone regeneration. Cell Prolif. 2021; 53(9):e12874. PMC: 7507571. DOI: 10.1111/cpr.12874. View